The evolution of aminoglycoside therapy: a single daily dose.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 8623702.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
After five decades of clinical use, aminoglycosides continue to be important antibiotics in the management of gram-negative infections. However, antimicrobial therapy with gentamicin, tobramycin, amikacin and netilmicin has been complicated by the risk of nephrotoxicity and ototoxicity. Considerable research has been conducted to determine the optimal aminoglycoside dosing method that will produce maximum efficacy with minimal toxicity. Experimental data and clinical experience suggest that aminoglycoside regimens modified from standard dosing (every eight to 12 hours) to once-daily dosing may provide improved clinical outcomes, with reduced toxicity and cost of therapy. Gentamicin, tobramycin and netilmicin may be administered in single daily dosages ranging from 4 to 7 mg per kg, and amikacin may be given in a dosage of 15 to 20 mg per kg once daily.